Abstract
Diabetes mellitus is a chronic metabolic disorder, characterized by glucose overproduction and glucose underutilization. Current therapy for T2DM includes drugs, like metformin, glitazones, sulphonyl ureas, etc. Extensive research has been carried out world wide on molecular targets for T2DM like PPARγ, PTP1B, DPP-IV, GSK-3, cannabinoid receptor, fructose-bisphosphatases, β3 adrenoceptor, etc. in the development of newer anti-diabetic agents. These therapeutic targets are quite important and most of them are suitable for in silico analysis. Hence, many molecular modeling and informatics studies like, molecular docking, pharmacophore mapping, 3DQSAR, virtual screening, quantum chemical studies, and pharmacoinformatics like bioinformatics and chemoinformatics studies have been performed on the drugs / leads / targets associated with T2DM. Several of these in silico efforts are exemplary studies; the methodologies adopted in these studies can be emulated in many other therapeutic areas. A review of the rational approaches reported in designing anti-diabetic agents is presented in this article.
Keywords: Molecular modeling, informatics, Diabetes mellitus, Dipeptidyl peptidase IV, Cannabinoid, β3-adrenoceptor, Glycogen synthase kinase-3, Protein tyrosine phosphatase-1B, Pyruvate dehydogenase kinase
Current Pharmaceutical Design
Title: Modeling and Informatics in Designing Anti-Diabetic Agents
Volume: 13 Issue: 34
Author(s): P. V. Bharatam, D. S. Patel, L. Adane, A. Mittal and S. Sundriyal
Affiliation:
Keywords: Molecular modeling, informatics, Diabetes mellitus, Dipeptidyl peptidase IV, Cannabinoid, β3-adrenoceptor, Glycogen synthase kinase-3, Protein tyrosine phosphatase-1B, Pyruvate dehydogenase kinase
Abstract: Diabetes mellitus is a chronic metabolic disorder, characterized by glucose overproduction and glucose underutilization. Current therapy for T2DM includes drugs, like metformin, glitazones, sulphonyl ureas, etc. Extensive research has been carried out world wide on molecular targets for T2DM like PPARγ, PTP1B, DPP-IV, GSK-3, cannabinoid receptor, fructose-bisphosphatases, β3 adrenoceptor, etc. in the development of newer anti-diabetic agents. These therapeutic targets are quite important and most of them are suitable for in silico analysis. Hence, many molecular modeling and informatics studies like, molecular docking, pharmacophore mapping, 3DQSAR, virtual screening, quantum chemical studies, and pharmacoinformatics like bioinformatics and chemoinformatics studies have been performed on the drugs / leads / targets associated with T2DM. Several of these in silico efforts are exemplary studies; the methodologies adopted in these studies can be emulated in many other therapeutic areas. A review of the rational approaches reported in designing anti-diabetic agents is presented in this article.
Export Options
About this article
Cite this article as:
Bharatam V. P., Patel S. D., Adane L., Mittal A. and Sundriyal S., Modeling and Informatics in Designing Anti-Diabetic Agents, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794239
DOI https://dx.doi.org/10.2174/138161207782794239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis of Iminosugars from Tetroses
Current Organic Synthesis Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPARγ Activation, Reduces Retinal Neovascularization
Current Neurovascular Research Type 1 Diabetes Treatments Based on Stem Cells
Current Diabetes Reviews Role of Endothelin in Uteroplacental Circulation and Fetal Vascular Function
Current Vascular Pharmacology Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis, Characterization and <i>in vivo</i> Evaluation of PEGylated PPI Dendrimer for Safe and Prolonged Delivery of Insulin
Drug Delivery Letters Hepatic Elimination of Drugs in Gestational Diabetes
Current Clinical Pharmacology n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Is there a Role for Cortisol in the Accumulation of Lipids in the Intima a Crucial Step of Atherogenesis?
Current Vascular Pharmacology Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis
Current HIV Research The Influence of Gender and Menopausal Status on Hba1c Variation in a Big Data Study of a Saudi Population
Current Diabetes Reviews